FORT LAUDERDALE, Fla. — Three clinical trials demonstrated rapid and sustained reduction of macular edema secondary to noninfectious uveitis in patients who received suprachoroidal CLS-TA, according to a speaker here.
“We found across all studies about 50% of all patients had a resolution of macular edema at 4 weeks,” Eduardo Uchiyama, MD, said at the Retina World Congress.
Uchiyama and colleagues pooled data from the DOGWOOD, PEACHTREE and AZALEA studies of patients with macular edema secondary to noninfectious uveitis. Patients received a suprachoroidal injection of CLS-TA
Uncategorized